FDA orders recall of machine used to clean medical scopes

Federal officials are ordering the recall of nearly 2,800 machines used to disinfect medical scopes.They blamed company violations that could lead to infections in patients.AP | Updated: November 14, 2015, 08:44 IST

WASHINGTON - Federal officials are ordering the recall of nearly 2,800 machines used to disinfect medical scopes. They blamed company violations that could lead to infections in patients.

The Food and Drug Administration said Friday that Custom Ultrasonics must recall all of its endoscope reprocessing devices, which are currently used at hospitals and medical clinics throughout the U.S. The devices are intended to kill bacteria and microorganisms found on flexible endoscopes after hospital procedures, so that they can be re-used safely. But the Warminster, Pennsylvania-based manufacturer has a history of violating federal rules for manufacturing and quality control.

The agency ordered the action under terms of a 2007 legal settlement with the company. The settlement bars the firm from making or distributing the machines. Custom Ultrasonics has continued to service the machines.

But FDA inspectors uncovered ongoing problems with the company's technology during an April inspection. Inspectors said the company still cannot show that its devices adequately wash and disinfect endoscopes.

"The FDA's recall order stemmed from the company's continued violations of federal law and the consent decree and is necessary to protect the public health," said Dr. William Maisel, the FDA's deputy director for medical devices.

A consent decree is a form of legal settlement in which a company agrees to court-ordered actions without admitting fault or guilt. The decree generally remains in effect until the FDA determines the company has fixed the problems.

The FDA says hospitals and medical facilities should switch to alternate machines to avoid possible infections.

The announcement follows a series of life-threatening bacterial outbreaks that have been tied to medical scopes at hospitals across the U.S.

Subscribe ETHealthworld Newsletter

Lyrica, known generically as pregabalin, was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain, which soon became its main market.

With this acquisition, Nephroplus will further strengthen its servicing capacity as the dominant dialysis centre network and will have a presence in 18 states of India with 176 centers across 97 cities.